Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nong Yang

Showing results (171-180 of 189) with videos related to

Pageof 19
Sort By:
European Journal of Cancer (Oxford, England : 1990)|December 2, 2025
Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 studyZhengbo Song, Ziming Li, Yiping Zhang, et al.
Cancer Communications (London, England)|July 17, 2024
Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS)Shun Lu, Xiaorong Dong, Hong Jian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2022
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R MutationsShun Lu, Xiaorong Dong, Hong Jian, et al.
Frontiers in Oncology|October 12, 2020
Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung AdenocarcinomaLong-Hua Guo, Ming-Feng Zhang, He-Long Zhang, et al.
JAMA Surgery|July 15, 2026
Surgical Outcomes of Perioperative Toripalimab in Stage III Resectable Non-Small Cell Lung Cancer: Post Hoc Analysis of the Neotorch Randomized Clinical TrialWentao Fang, Yiyang Wang, Wenxiang Wang, et al.
JAMA|January 16, 2024
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical TrialShun Lu, Wei Zhang, Lin Wu, et al.
Translational Lung Cancer Research|July 28, 2018
A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panelYi-Long Wu, Chang-Li Wang, Mei-Lin Liao, et al.
Thoracic Cancer|October 21, 2022
Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitorWenxian Wang, Qian Wang, Chunwei Xu, et al.
Thoracic Cancer|November 29, 2022
Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancerShirong Zhang, Wenxian Wang, Chunwei Xu, et al.
Thoracic Cancer|September 18, 2023
Expert consensus on the diagnosis and treatment of RET gene fusion non-small cell lung cancer in ChinaXingxiang Pu, Chunwei Xu, Qian Wang, et al.
Pageof 19

Showing results (171-180 of 189) with videos related to

Sort By:
Pageof 19
European Journal of Cancer (Oxford, England : 1990)|December 2, 2025
Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 studyZhengbo Song, Ziming Li, Yiping Zhang, et al.
Cancer Communications (London, England)|July 17, 2024
Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS)Shun Lu, Xiaorong Dong, Hong Jian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2022
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R MutationsShun Lu, Xiaorong Dong, Hong Jian, et al.
Frontiers in Oncology|October 12, 2020
Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung AdenocarcinomaLong-Hua Guo, Ming-Feng Zhang, He-Long Zhang, et al.
JAMA Surgery|July 15, 2026
Surgical Outcomes of Perioperative Toripalimab in Stage III Resectable Non-Small Cell Lung Cancer: Post Hoc Analysis of the Neotorch Randomized Clinical TrialWentao Fang, Yiyang Wang, Wenxiang Wang, et al.
JAMA|January 16, 2024
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical TrialShun Lu, Wei Zhang, Lin Wu, et al.
Translational Lung Cancer Research|July 28, 2018
A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panelYi-Long Wu, Chang-Li Wang, Mei-Lin Liao, et al.
Thoracic Cancer|October 21, 2022
Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitorWenxian Wang, Qian Wang, Chunwei Xu, et al.
Thoracic Cancer|November 29, 2022
Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancerShirong Zhang, Wenxian Wang, Chunwei Xu, et al.
Thoracic Cancer|September 18, 2023
Expert consensus on the diagnosis and treatment of RET gene fusion non-small cell lung cancer in ChinaXingxiang Pu, Chunwei Xu, Qian Wang, et al.
Pageof 19